Virome Capture Sequencing Enables Sensitive Viral Diagnosis
By LabMedica International staff writers Posted on 05 Oct 2015 |
Insensitivity and technical complexity have impeded the implementation of high-throughput nucleic acid sequencing in differential diagnosis of viral infections in clinical laboratories.
A breakthrough genetic testing method, which is as sensitive as the gold standard polymerase chain reaction assays, enables simultaneous testing for hundreds of different viruses and provides near complete sequence of their genomes promises to give clinicians a powerful new tool to detect and sequence viruses.
Scientists at Columbia University (New York, NY, USA) generated facsimiles of clinical specimens in a background of nucleic acid (NA) extracted from normal human lung tissue, EDTA-blood, or serum. The samples were spiked with viral NA and quantitated by virus-specific TaqMan real-time (reverse transcription) PCR (qPCR). They developed the Virome-Capture-Sequencing platform for Vertebrate viruses (VirCapSeq-VERT) which enables simultaneous testing for hundreds of different viruses and providing near complete sequence of their genomes.
Clinical samples included a human nasal swab sample known to be positive for Enterovirus D68 (EV-D68) and serum samples from hemophilia patients co-infected with Hepatitis C virus (HCV), GB virus C (GBV-C), human immunodeficiency virus (HIV), and torque teno virus (TTV). NA from cell culture or blood, serum, or tissue samples was extracted using the easyMAG system (bioMérieux; Marcy l’Etoile, France) or AllPrep DNA/RNA kits (Qiagen; Hilden, Germany). The PCR products were purified using Agencourt Ampure DNA purification beads (Beckman Coulter; Brea, CA, USA) and quantitated for Illumina sequencing.
The use of VirCapSeq-VERT resulted in a 100- to 10,000-fold increase in viral reads from blood and tissue homogenates compared to conventional Illumina sequencing using established virus enrichment procedures, including filtration, nuclease treatments, and RiboZero ribosomal ribonucleic acid (rRNA) subtraction. VirCapSeq-VERT had a limit of detection comparable to that of agent-specific real-time PCR in serum, blood, and tissue extracts. Furthermore, the method identified novel viruses whose genomes were approximately 40% different from the known virus genomes used for designing the probe library. The VirCapSeq-VERT platform is ideally suited for analyses of virome composition and dynamics.
Thomas Briese, PhD, a professor and lead author of the study, said, “If you have patients you suspect has a viral disease, you can now for a very reasonable amount of money, definitively characterize all the viruses present in those individuals in order to figure out how they should be treated.” VirCapSeq-VERT costs approximately USD 40 when testing for 20 patients/samples, comparing favorably with other procedures like rRNA depletion which cost approximately USD 65 per sample. The study was published on September 22, 2015, in the journal mBIO.
Related Links:
Columbia University
bioMérieux
Qiagen
A breakthrough genetic testing method, which is as sensitive as the gold standard polymerase chain reaction assays, enables simultaneous testing for hundreds of different viruses and provides near complete sequence of their genomes promises to give clinicians a powerful new tool to detect and sequence viruses.
Scientists at Columbia University (New York, NY, USA) generated facsimiles of clinical specimens in a background of nucleic acid (NA) extracted from normal human lung tissue, EDTA-blood, or serum. The samples were spiked with viral NA and quantitated by virus-specific TaqMan real-time (reverse transcription) PCR (qPCR). They developed the Virome-Capture-Sequencing platform for Vertebrate viruses (VirCapSeq-VERT) which enables simultaneous testing for hundreds of different viruses and providing near complete sequence of their genomes.
Clinical samples included a human nasal swab sample known to be positive for Enterovirus D68 (EV-D68) and serum samples from hemophilia patients co-infected with Hepatitis C virus (HCV), GB virus C (GBV-C), human immunodeficiency virus (HIV), and torque teno virus (TTV). NA from cell culture or blood, serum, or tissue samples was extracted using the easyMAG system (bioMérieux; Marcy l’Etoile, France) or AllPrep DNA/RNA kits (Qiagen; Hilden, Germany). The PCR products were purified using Agencourt Ampure DNA purification beads (Beckman Coulter; Brea, CA, USA) and quantitated for Illumina sequencing.
The use of VirCapSeq-VERT resulted in a 100- to 10,000-fold increase in viral reads from blood and tissue homogenates compared to conventional Illumina sequencing using established virus enrichment procedures, including filtration, nuclease treatments, and RiboZero ribosomal ribonucleic acid (rRNA) subtraction. VirCapSeq-VERT had a limit of detection comparable to that of agent-specific real-time PCR in serum, blood, and tissue extracts. Furthermore, the method identified novel viruses whose genomes were approximately 40% different from the known virus genomes used for designing the probe library. The VirCapSeq-VERT platform is ideally suited for analyses of virome composition and dynamics.
Thomas Briese, PhD, a professor and lead author of the study, said, “If you have patients you suspect has a viral disease, you can now for a very reasonable amount of money, definitively characterize all the viruses present in those individuals in order to figure out how they should be treated.” VirCapSeq-VERT costs approximately USD 40 when testing for 20 patients/samples, comparing favorably with other procedures like rRNA depletion which cost approximately USD 65 per sample. The study was published on September 22, 2015, in the journal mBIO.
Related Links:
Columbia University
bioMérieux
Qiagen
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia